What's in Technische Universität Dresden's pipeline?

Technische Universität Dresden has 18 drugs in our index: 12 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Technische Universität Dresden's portfolio?

Top competitors by shared drug class: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, University of Pennsylvania, GlaxoSmithKline, Janssen Korea, Ltd., Korea, University Hospital, Ghent.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/technische-universit-t-dresden.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Technische Universität Dresden — Portfolio Competitive Intelligence Brief

Technische Universität Dresden pipeline: 12 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 4 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
all-trans retinoid acid	all-trans retinoid acid	marketed
Ciclosporine A	Ciclosporine A	marketed
Midazolam (sedative)	Midazolam (sedative)	marketed	Benzodiazepine	GABA-A receptor	Neurology / Anesthesia
Gilteritinib (GILT)	Gilteritinib (GILT)	marketed	FLT3 inhibitor	FLT3 (FMS-like tyrosine kinase 3)	Oncology
amine fluoride/stannous fluoride	amine fluoride/stannous fluoride	marketed	Topical fluoride agent		Dental/Oral Health
Piritramid (analgetic)	Piritramid (analgetic)	marketed	Opioid analgesic	Mu opioid receptor	Pain Management
Fludarabine (Flud)	Fludarabine (Flud)	marketed	Purine analog antimetabolite	Ribonucleotide reductase, DNA polymerase	Oncology
Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	marketed	Combination chemotherapy (nucleoside analog + topoisomerase II inhibitors)	DNA polymerase (cytarabine); Topoisomerase II (amsacrine, mitoxantrone)	Oncology
Cytarabine Dosage	Cytarabine Dosage	marketed
randomization between two established Chemotherapies	randomization between two established Chemotherapies	marketed			Oncology
Elidel-Creme	Elidel-Creme	marketed	Calcineurin inhibitor (topical immunosuppressant)	Calcineurin; macrophilin-12	Dermatology/Immunology
Adapalen	Adapalen	marketed		Aspartate aminotransferase, cytoplasmic, Glycine receptor subunit alpha-1, Retinoic acid receptor alpha	Metabolic

Therapeutic area mix

Oncology · 5
Hematology · 2
Dermatology/Immunology · 1
Metabolic · 1
Neurology / Anesthesia · 1
Dental/Oral Health · 1
Pain Management · 1
Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 2 shared drug classes
University of Pennsylvania · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Janssen Korea, Ltd., Korea · 2 shared drug classes
University Hospital, Ghent · 2 shared drug classes
University of California, San Francisco · 2 shared drug classes
Eisai Inc. · 2 shared drug classes
Alza Corporation, DE, USA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Technische Universität Dresden:

Cite this brief

Drug Landscape (2026). Technische Universität Dresden — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/technische-universit-t-dresden. Accessed 2026-05-16.